Abstract
Background: We conducted a prospective clinical trial of combination neoadjuvant chemotherapy, transoral robotic surgery (TORS), and customized adjuvant therapy in patients with locally advanced laryngo-hypopharyngeal cancer. Methods: Between September 2008 and August 2016, 35 patients were enrolled in this clinical trial. Results: Twenty patients had hypopharyngeal cancer and 15 had laryngeal cancer. Twenty-nine patients (82.9%) had T3 disease and six patients (17.1%) had T4 disease, while 12 patients (34.3%) had stage III disease and 23 patients (65.7%) had stage IV disease. The 3-year disease-specific survival rate was 82.4% and the 3-year disease-free survival rate was 69.48%. Decannulation was successful in 31 of 34 patients at an average of 18 days postoperatively. Among all patients, 83% exhibited a favorable subjective swallowing status, while five patients (14.4%) became dependent on feeding tubes. Conclusions: Neoadjuvant chemotherapy combined with TORS and customized adjuvant therapy, based on detailed pathological information, afforded favorable oncological outcomes and preserved organ functionalities in T3–T4 laryngo-hypopharyngeal cancer.
Original language | English |
---|---|
Pages (from-to) | 864-871 |
Number of pages | 8 |
Journal | Annals of surgical oncology |
Volume | 25 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2018 Apr 1 |
Bibliographical note
Publisher Copyright:© 2017, Society of Surgical Oncology.
All Science Journal Classification (ASJC) codes
- Surgery
- Oncology